Popular Weight-Loss Drug May Cut Heart Attack Risk by 54%, New Studies Find
New research on tirzepatide, the drug behind Zepbound and Mounjaro, suggests it could significantly lower the risk of major cardiovascular event.
Original Source
Read the full article at Inc →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.